Sign up for ICER's Weekly View Newsletter

 

Weekly View


August 28, 2026

From the desk of Priya Ranade

Good morning, everyone.

ICER announced new members for ICER’s Patient Council this week, which advises on ICER’s patient engagement strategy, outreach, and process for input into ICER assessments and broader initiatives. New members represent a wide range of patient communities, and all have participated in a recent ICER assessment. This new cohort will serve a two-year term through 2028.

 

Sarah K. Emond, MPP, ICER’s President and CEO stated:

 

“In partnership with our inaugural council, ICER’s patient engagement program has grown into what is increasingly seen as best-practice throughout the health technology assessment community. This new group of accomplished advocates will continue to build on this vital work. Their collective experience in advocating for access to treatments will inform ICER’s ever-evolving approach to incorporating patient voices into every stage of our research.”

 

The new members include:

 

  • Julie Grutzmacher, Senior Director of Patient Advocacy and Population Health Initiatives, Prevent Blindness

 

 

  • Dean Suhr, President & Co-Founder, MLD Foundation

 

 

To ensure continuity, two inaugural members will remain on the Council:


  • Tiffany Westrich-Robertson (ICER Patient Council Co-Chair), CEO, International Foundation for Autoimmune & Autoinflammatory Arthritis (AiArthritis)


  • Dina Thachet, Lupus Patient Advocate, Lupus and Allied Diseases Association (LADA)


Additionally, Catherine Koola Fischer, ICER’s Senior Director of Patient Engagement will continue as Co-Chair of the Patient Council. 

Let's see what else happened this week...

 
Pharmaceutical News

MUST READS


Why businesses struggle to forecast health costs

Axios


More US employers to drop weight-loss drugs in 2027, as healthcare costs increase

Reuters

Axios reported that employers' best-laid strategies for addressing steep health cost increases next year may be overly optimistic, according to a new survey the Business Group on Health. Corporations are consistently underestimating their future costs due to extreme volatility in health markets, underscoring the need to overhaul strategies for providing worker benefits.


Reuters also covered the survey findings and highlighted that about 14% of employers in the United States have already or plan to drop GLP-1 drugs in 2027, as companies see rising healthcare costs.

White House to Announce New Drug Pricing Deals With Biotechs

Bloomberg

The Trump administration plans to announce a new round of drug-pricing agreements with several midsized biotech companies on Monday, according to people familiar with the matter.

The companies will agree to provide discounts on outpatient drugs to state Medicaid programs so that the prices states pay align with what the companies charge in foreign countries, the people said. Participation by state Medicaid programs is optional.

Trump offered state Medicaid programs lower prices on weight-loss drugs. Most are rejecting the deal.

Politico

President Trump promised last year that obese Americans on Medicaid would gain access to drugs known as GLP-1s, like Wegovy and Zepbound, if the states where they live signed on with his administration to negotiate prices directly with manufacturers.


Nine months later, Medicaid patients’ access to the drugs has shrunk. Only Indiana has publicly signed on with the administration. Some states have stopped covering the medications for Medicaid patients who need them for weight loss. Others are considering ending coverage. Most states told POLITICO they will not participate. States opting out of coverage — including Maine, New Mexico and Oklahoma — cited budget constraints and concerns about the long-term financial sustainability of Trump’s model.

The Medicare GLP-1 Discount Has One Big Catch: Some Sick Patients Don’t Qualify

KFF Health News


Drugstores say Medicare's $50 obesity drug program is catching on

NPR

According to KFF, about 1 in 5 American adults have taken a GLP-1 medication, and most of them, including those with health insurance, say the drugs are difficult to afford. Federal law has long barred Medicare from covering drugs prescribed solely for weight loss, which is why the Medicare GLP-1 Bridge program made a big splash when it launched in July.


But the $50 price under the Bridge program applies only to people using the drug solely for weight loss. Anyone who has a qualifying medical condition that the Food and Drug Administration has approved GLP-1s to treat, such as Type 2 diabetes or moderate to severe obstructive sleep apnea, is instead routed back to their Medicare Part D prescription drug plan, which can require copays of hundreds of dollars a month for GLP-1s.


However, those that do qualify are opting in. NPR reported that:


  • Walgreens chief pharmacy officer Rick Gates said: "We expected there would be uptake...I think there's been a little bit more uptake than we even expected."



  • CVS says it has filled more than 100,000 Bridge prescriptions as of mid-August. 


  • Walmart didn't provide a number for Bridge program prescriptions it has filled, but it did say that those prescriptions have been growing week over week.

OTHER HEADLINES

 
 

Key Upcoming Dates

 
  • 9/16: Parkinson's Disease — Evidence Report
  • 10/1: Hypertension — Evidence Report
  • 10/15: Friedrich's Ataxia — Draft Evidence Report

Learn more about ICER’s ongoing and recently completed reports:

Email info@icer.org for more information.

When you make a gift to ICER, you help keep ICER independent.  

 
 
 
 
 
LinkedIn Share This Email